PNC Financial Services Group
MBRX icon

PNC Financial Services Group’s Moleculin Biotech MBRX Stock Holding History

PNC Financial Services Group’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3
Closed -$13K – 4121
2018
Q3 		$13K Hold
3
– – ﹤0.01% 3581
2018
Q2 		$14K Hold
3
– – ﹤0.01% 3570
2018
Q1 		$14K Hold
3
– – ﹤0.01% 3581
2017
Q4 		$15K Buy
+3
New +$13K ﹤0.01% 3529

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIC
Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PNC Financial Services Group's MBRX Position: Q4 2018 in Review

PNC Financial Services Group sold out of Moleculin Biotech (MBRX) in Q4 2018, closing a stake of 3 shares — an estimated $13K sold.

PNC Financial Services Group first reported a position in MBRX in Q4 2017 and held it in 4 quarters. The position peaked at $15K in Q4 2017. 20 funds tracked by Wall St. Rank hold MBRX as of Q4 2018.

  • PNC Financial Services Group reported no remaining Moleculin Biotech position as of Q4 2018 after selling out during the quarter.
  • PNC Financial Services Group sold 3 Moleculin Biotech shares in Q4 2018, an estimated $13K.
  • PNC Financial Services Group first reported a position in Moleculin Biotech in Q4 2017 and held it in 4 quarters.
  • PNC Financial Services Group's Moleculin Biotech position peaked at $15K in Q4 2017.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2018.

Based on PNC Financial Services Group's 13F filing for Q4 2018, filed 8 Feb 2019.